Xin Jia, Xiao-Ping Liu, Wei Guo, Jiang Xiong, Hong-Peng Zhang, Xiao-Hui Ma, Xin Du, Min-Hong Zhang
Department of Vascular Surgery, Chinese PLA General Hospital, Beijing 100853, China.
Vascular. 2011 Oct;19(5):257-61. doi: 10.1258/vasc.2011.oa0289. Epub 2011 Sep 8.
The purpose of this study was to evaluate outcomes of the endovascular treatment of splenic artery aneurysms (SAAs) and pseudoaneurysms (SAPAs). From April 2003 to December 2009, 12 patients (mean age 46.8 years, range 29-58) with SAAs (n = 9) or SAPAs (n = 3) underwent endovascular treatment. Four patients were asymptomatic and three had ruptured aneurysms. Lesions were in the proximal splenic artery (n = 3), intermediate splenic artery (n = 3) and distal splenic artery (n = 6). Endovascular procedures included embolization by sac packing (n = 5), sandwich occlusion of the splenic artery (n = 4) or stent graft deployment (n = 3). Computed tomography (CT) was done before the operation, 3 and 12 months after the operation, then yearly. Endovascular treatment was successful at the first attempt in all 12 (100%) patients, with complete angiographic exclusion of the aneurysm at the end of the operation. The mean amount of contrast medium used was 165 mL (range 100-230), and the mean total procedure time was 92 minutes (range 55-160). No major complications occurred. Postoperational CT scans showed splenic multisegmental infarcts in eight patients (66.7%, 8/12) and among them postembolization syndrome developed in six patients, manifesting as abdominal pain and fever. The mean follow-up was 32 months (range 9-51). No patient demonstrated gross evidence of aneurysm sac growth, and no significant decrease in aneurysm sac size postintervention was noted on follow-up. The endovascular management of SAAs and SAPAs is safe and effective and may induce less mortality than open surgery. Regardless of the etiology, endovascular treatment can provide excellent mid-term results.
本研究的目的是评估脾动脉瘤(SAA)和假性脾动脉瘤(SAPA)血管内治疗的效果。2003年4月至2009年12月,12例(平均年龄46.8岁,范围29 - 58岁)患有SAA(n = 9)或SAPA(n = 3)的患者接受了血管内治疗。4例患者无症状,3例动脉瘤破裂。病变位于脾动脉近端(n = 3)、脾动脉中段(n = 3)和脾动脉远端(n = 6)。血管内操作包括瘤腔填充栓塞(n = 5)、脾动脉夹心封堵(n = 4)或支架植入(n = 3)。术前、术后3个月和12个月进行计算机断层扫描(CT),之后每年进行一次。12例(100%)患者首次血管内治疗均成功,术后造影显示动脉瘤完全排除。平均造影剂用量为165 mL(范围100 - 230),平均总手术时间为92分钟(范围55 - 160)。未发生重大并发症。术后CT扫描显示8例患者(66.7%,8/12)出现脾脏多节段梗死,其中6例患者发生栓塞后综合征,表现为腹痛和发热。平均随访32个月(范围9 - 51)。没有患者出现动脉瘤瘤腔增大的明显证据,随访期间未发现干预后动脉瘤瘤腔大小有显著减小。SAA和SAPA的血管内治疗安全有效,与开放手术相比可能死亡率更低。无论病因如何,血管内治疗均可提供良好的中期效果。